Market Overview

UPDATE: BMO Capital Markets Initiates Intercept Pharmaceuticals at Outperform on Outlook

Related ICPT
Intercept Announces Publication Of Meta-Analysis From The Global PBC Study Group In Gastroenterology
The Top 25 Analysts On Wall Street
Making Money With Charles Payne: 12/22/14 (Fox Business)

BMO Capital Markets initiated coverage on Intercept Pharmaceuticals (NASDAQ: ICPT) with an Outperform rating and a $31 price target.

BMO Capital Markets said, "Our positive outlook is supported by a proprietary platform of bile acid analogs, a deep pipeline of clinical candidates, and a lead opportunity in Primary Biliary Cirrhosis (PBC), a rare orphan disease supporting a $500 million–$1 billion opportunity. With phase 3 data for lead bile acid analog OCA (INT-747) expected by mid-2013, phase 2 data in PBC is compelling, in our opinion, and should support a clear benefit in patients failing current standard bile acid therapy with ursodiol (URSO)."

Intercept Pharmaceuticals closed at $18.75 on Friday.

Latest Ratings for ICPT

DateFirmActionFromTo
Dec 2014CitigroupMaintainsBuy
Dec 2014Bank of AmericaReinstatesBuy
Dec 2014FBR CapitalMaintainsUnderperform

View More Analyst Ratings for ICPT
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (ICPT)

Around the Web, We're Loving...

Get Benzinga's Newsletters